Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new Cochrane Review says Cognitive Behavioural Therapy (CBT) may be effective in reducing the negative impact that tinnitus can have on quality of life.

Researchers from the Cochrane ENT Disorders Group at the Nuffield Department of Surgical Sciences collected and analysed 28 relevant studies (mostly from Europe) with a total of 2733 participants with tinnitus lasting for at least three months. The duration of the CBT ranged from 3 to 22 weeks, mostly given in hospitals or online. CBT was compared with no intervention/waiting list, audiological care, tinnitus retraining therapy (TRT) or another active control (e.g. information, relaxation). However, there is an absence of evidence at 6 or 12 months follow-up. 

The team identified that CBT probably reduces the negative impact of tinnitus on quality of life at the end of treatment compared with audiological care (moderate-certainty evidence), and may reduce it compared with tinnitus retraining therapy, other active controls or no intervention/being on a waiting list (all low-certainty evidence), but it is unknown whether this lasts. CBT may also slightly reduce depression at the end of treatment (low-certainty evidence). 

The Cochrane authors also found some low- to moderate-certainty evidence that adverse effects may be rare in adults with tinnitus receiving CBT, but this needs further investigation. 

Read the full Cochrane Review

Similar stories

EndoNET randomises first patient of 2023

A trial investigating how effective endocrine treatment is, prior to surgery in post-menopausal women with breast cancer, has randomised its first patient of the year.

New Cochrane review on antihistamines for motion sickness

A new systematic review from Cochrane ENT at the Nuffield Department of Surgical Sciences says antihistamines are likely to reduce the risk of developing motion sickness (travel sickness) in susceptible adults under naturally occurring conditions of movement, but they may be more likely to cause drowsiness than placebo.

Life-changing results from DRWF Human Islet Isolation Facility at NDS

A new documentary film launched by the Diabetes Research and Wellness Foundation (DRWF) on World Diabetes Day 2022 features an interview with Professor Paul Johnson, as he describes life-changing results from the DRWF Human Islet Isolation Facility at the Nuffield Department of Surgical Sciences (NDS).

Blog posts

Staff Census: We need you!

All Medical Sciences staff are invited to log into HR self-service and ensure their contact, diversity background and disability details are up to date. Between 6% and 27% of staff in the Division are missing their diversity data which makes it difficult to complete statutory reporting, understand or track our population changes and to plan actions around staff diversity and equality – make sure your data is complete today!

Oxford MedSci goes silver: 10 Years of Athena SWAN

The Medical Sciences Division is celebrating 10 years since its first Athena Swan bronze application, and the first year in which all 16 of its departments have achieved a silver award. The silver award recognises commitment to gender equality, understanding culture and context, and more. Read about our department’s hard work and innovation.

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.